Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 3.90%201.8M | 4.14%896.53M | 4.25%643.21M | 3.55%433.66M | 17.47%194.23M | 31.49%860.93M | 44.64%616.97M | 62.83%418.81M | 19.10%165.34M | 28.46%654.73M |
Operating revenue | 3.90%201.8M | 4.14%896.53M | 4.25%643.21M | 3.55%433.66M | 17.47%194.23M | 31.49%860.93M | 44.64%616.97M | 62.83%418.81M | 19.10%165.34M | 28.46%654.73M |
Total operating cost | 8.22%145.02M | -1.51%600.27M | 2.10%440.93M | -3.51%291.52M | 9.25%134.01M | 24.26%609.49M | 25.47%431.84M | 38.01%302.13M | 15.61%122.67M | 22.36%490.5M |
Operating cost | 2.96%21.04M | 0.11%95.26M | -1.62%67.48M | -3.36%44.9M | 3.48%20.43M | 24.93%95.15M | 34.02%68.59M | 46.14%46.45M | 23.39%19.75M | 22.62%76.17M |
Operating tax surcharges | 14.20%3.28M | 23.94%12.98M | 27.89%9.3M | 40.82%6.35M | 127.05%2.87M | 13.36%10.47M | 41.74%7.27M | 17.09%4.51M | -34.25%1.26M | 1.57%9.24M |
Operating expense | 13.40%99.41M | -1.21%397M | 3.90%291.67M | -1.70%196.85M | 10.38%87.66M | 29.26%401.87M | 31.27%280.73M | 50.88%200.24M | 10.79%79.42M | 19.51%310.91M |
Administration expense | 2.44%14.37M | 6.13%61.54M | 6.72%44.91M | 3.68%28.8M | -0.81%14.03M | 14.49%57.99M | 9.78%42.08M | 8.91%27.77M | 31.17%14.14M | 13.85%50.65M |
Financial expense | -34.23%-904.39K | 56.21%-5.16M | 59.72%-3.6M | 49.26%-2.77M | -53.69%-673.78K | -1.16%-11.78M | -45.52%-8.93M | -32.24%-5.46M | 66.55%-438.4K | -172.37%-11.65M |
-Interest expense (Financial expense) | 26.06%71.56K | 21.36%128.08K | 31.23%85.88K | 24.36%79.66K | -93.44%56.77K | -71.95%105.53K | -62.09%65.44K | -62.89%64.06K | --865.17K | --376.23K |
-Interest Income (Financial expense) | -32.32%-1M | 55.11%-5.4M | 58.49%-3.78M | 47.71%-2.91M | 42.95%-758.2K | 0.54%-12.02M | -43.15%-9.1M | -28.77%-5.57M | -0.31%-1.33M | -175.93%-12.09M |
Research and development | -19.19%7.84M | -30.70%38.65M | -25.98%31.16M | -39.17%17.4M | 13.62%9.7M | 1.08%55.77M | 0.63%42.1M | -2.01%28.6M | 21.42%8.53M | 88.44%55.18M |
Credit Impairment Loss | 11.61%924K | 68.63%-2.26M | 74.05%-1.63M | 76.23%-1.82M | 142.42%827.87K | -883.43%-7.2M | -181.27%-6.27M | -318.95%-7.66M | -572.97%-1.95M | -141.40%-732.27K |
Asset Impairment Loss | ---- | -1,987.41%-42.24M | ---- | ---- | ---- | ---2.02M | ---- | ---- | ---- | ---- |
Other net revenue | ||||||||||
Invest income | 39.39%-1.29M | 44.84%-1.05M | 25.16%-2.12M | -37.40%-1.95M | -157.64%-2.14M | -133.46%-1.9M | -196.19%-2.83M | -136.20%-1.42M | -101.83%-828.72K | -67.08%5.68M |
-Including: Investment income associates | 34.96%-913.03K | 25.24%-4.15M | 16.12%-3.33M | 3.65%-2.4M | -28.96%-1.4M | 8.78%-5.55M | 13.23%-3.97M | 18.93%-2.49M | 29.29%-1.09M | -80.34%-6.09M |
Other revenue | 4.36%752.55K | -55.10%3.95M | 119.97%2.38M | 250.06%1.53M | 211.45%721.14K | 21.73%8.79M | -82.76%1.08M | -92.21%436.24K | -56.05%231.54K | 24.95%7.22M |
Operating profit | -4.15%57.16M | 2.23%254.66M | 13.44%200.92M | 29.48%139.89M | 48.62%59.63M | 41.22%249.11M | 98.23%177.12M | 134.96%108.04M | 23.31%40.13M | 32.00%176.4M |
Add:Non operating Income | ---- | 1,469.86%7.2K | --7.2K | --7.2K | ---- | -92.49%458.64 | ---- | ---- | ---- | --6.1K |
Less:Non operating expense | -22.54%111.95K | -20.15%1.31M | 28.73%578.97K | 50.73%475.35K | -10.68%144.53K | -12.61%1.64M | -66.01%449.76K | 104.36%315.36K | 607.54%161.8K | 74.71%1.87M |
Total profit | -4.10%57.05M | 2.38%253.36M | 13.40%200.34M | 29.43%139.43M | 48.86%59.49M | 41.79%247.48M | 100.69%176.67M | 135.05%107.72M | 22.90%39.96M | 31.66%174.53M |
Less:Income tax cost | 7.63%7.6M | 19.76%34.39M | 18.97%26.03M | 50.92%17.59M | 243.47%7.06M | 41.63%28.71M | 140.79%21.88M | 196.55%11.65M | -49.17%2.06M | 11.29%20.27M |
Net profit | -5.69%49.45M | 0.10%218.98M | 12.61%174.31M | 26.82%121.84M | 38.31%52.43M | 41.81%218.77M | 96.08%154.79M | 129.28%96.07M | 33.14%37.91M | 34.91%154.26M |
Net profit from continuing operation | -5.69%49.45M | 0.10%218.98M | 12.61%174.31M | 26.82%121.84M | 38.31%52.43M | 41.81%218.77M | 96.08%154.79M | 129.28%96.07M | 33.14%37.91M | 34.91%154.26M |
Less:Minority Profit | 2.08%-82.73K | -9.96%-352.2K | 10.26%-250.87K | 12.88%-167.19K | 17.92%-84.48K | 20.87%-320.31K | 11.08%-279.55K | 9.07%-191.9K | 8.40%-102.93K | 26.96%-404.79K |
Net profit of parent company owners | -5.68%49.53M | 0.11%219.33M | 12.57%174.56M | 26.74%122.01M | 38.15%52.51M | 41.65%219.09M | 95.65%155.07M | 128.59%96.26M | 32.98%38.01M | 34.61%154.67M |
Earning per share | ||||||||||
Basic earning per share | -10.71%0.25 | -3.42%1.13 | 9.64%0.91 | 27.45%0.65 | 40.00%0.28 | 40.96%1.17 | 97.62%0.83 | 121.74%0.51 | 33.33%0.2 | 36.07%0.83 |
Diluted earning per share | -10.71%0.25 | -3.42%1.13 | 9.64%0.91 | 27.45%0.65 | 40.00%0.28 | 40.96%1.17 | 97.62%0.83 | 121.74%0.51 | 33.33%0.2 | 36.07%0.83 |
Other composite income | ||||||||||
Total composite income | -5.69%49.45M | 0.10%218.98M | 12.61%174.31M | 26.82%121.84M | 38.31%52.43M | 41.81%218.77M | 96.08%154.79M | 129.28%96.07M | 33.14%37.91M | 34.91%154.26M |
Total composite income of parent company owners | -5.68%49.53M | 0.11%219.33M | 12.57%174.56M | 26.74%122.01M | 38.15%52.51M | 41.65%219.09M | 95.65%155.07M | 128.59%96.26M | 32.98%38.01M | 34.61%154.67M |
Total composite income of minority owners | 2.08%-82.73K | -9.96%-352.2K | 10.26%-250.87K | 12.88%-167.19K | 17.92%-84.48K | 20.87%-320.31K | 11.08%-279.55K | 9.07%-191.9K | 8.40%-102.93K | 26.96%-404.79K |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | -- | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.